Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms

Key facts

Sponsor

University of California, San Francisco

Principal Investigator

Emily Bergsland, MD

University of California, San Francisco

Intervention

Hereditary Cancer Panel(diagnostic_test)

Enrollment

300 enrolled

Eligibility

18 years · All sexes

Timeline

2023 – 2026

Study locations (3)

• University of California, Los Angeles, Los Angeles, California, United States
• Univeristy of California, San Diego, San Diego, California, United States
• University of California, San Francisco, San Francisco, California, United States

Collaborators

University of California Pancreatic Cancer Consortium (UCPCC)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Serotonin-producing neuroendocrine tumor of pancreas

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT06592989
  A Clinical Study of Sorafenib Combined With Gefitinib for the Treatment of pNET
  Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

See all trials for Serotonin-producing neuroendocrine tumor of pancreas →